Figure 3 | Scientific Reports

Figure 3

From: Author Correction: Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy

Figure 3

Changes in mean central foveal thickness during the 36-month anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical neovascular age-related macular degeneration (nAMD). The mean central foveal thickness showed a significant decrease when comparing from baseline through the 36 months follow-up for the groups. However, there was no significant difference between the groups in central foveal thickness at 3, 12, 24, and 36 months.

Back to article page